Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Autores: Northend, M. (Autor de correspondencia); Wilson, W.; Osborne, W.; Fox, C. P. ; Davies, A. J.; El-Sharkawi, D.; Phillips, E. H.; Sim, H. W.; Sadullah, S.; Shah, N.; Peng, Y. Y.; Qureshi, I.; Addada, J.; Figueroa Mora, María del Rocío; Phillips, N.; Kuhnl, A.; Davies, E.; Wrench, D.; McKay, P.; Karpha, I.; Cowley, A.; Karim, R.; Challenor, S.; Singh, V.; Burton, C.; Auer, R.; Williams, C.; Cunningham, J.; Broom, A.; Arasaretnam, A.; Roddie, C.; Menne, T.; Townsend, W.